Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Biopharma talent wars heat up as openings spike in 2023

By Brian Buntz | August 16, 2023

Woman, pills and medical science research or scientist development for future drugs, medicine or product. Face of female worker in laboratory for pharmaceutical discovery, innovation and analysis.

[See Less/Adobe Stock]

The biopharma industry had a lull in job opening growth from late 2022 and into early 2023. At that time, some early stage companies struggled to secure funding, while larger firms adopted a more cautious posture, according to recent research from the global real-estate firm JLL. Madeline Holmes, a senior research analyst at the company, noted, “Job Openings was something that we looked into as a metric of potential future growth.”

While biopharma layoffs remain a common occurrence, a turnaround could be underway — at least for bigger well-heeled players. The appetite for life sciences talent has ramped up since March of this year. June 2023 marked the sixth highest number of biopharma job openings in any month on record, in line with peaks in 2022. Year-over-year, June postings rose 11%.

Holmes provided some geographical context, noting that Massachusetts saw the most biopharma job postings in the first half of 2023 with 17,732, followed by California with 17,316.

The top companies posting jobs included Johnson & Johnson, Sanofi, Icon, Pfizer and Takeda.

Why biopharma turnaround stands out

The biopharma job growth data stands out when looking across sectors. Elsewhere, JLL had noticed “a bit of a pullback,” said Amber Schiada, JLL research director. “This trend in the biopharma industry is counter to what we’re seeing across larger parts of the job openings across industries.”

JLL analysts see the recent spike in biopharma postings as a leading indicator of industry growth. Such data could signal expanded real estate needs for lab space going forward if the hiring trend continues, Holmes noted.

Biopharma job openings

A tale of two biopharma industries

The growth trend, however, is not universal. JLL’s analysis mirrors what Jefferies analyst Michael Yee described earlier this year as a “filtering of the haves and have notes.” In an interview with WSJ, Yee described a survival of the fittest dynamic in the industry, juxtaposing capital-rich companies with “great assets and pipelines” with “bleaker prospects.”

Schiada observed a similar dynamic, “If you think about the larger companies versus the startups and how they’re driven and the capital sources they rely on, there are marked differences,” she said. The latter relies on venture capital backing, which is down. Consequently, startups are either preserving capital or, as it runs dry, making cuts. “On the flip side, a lot of these larger pharma companies have been hungry to acquire and obtain new intellectual property.” Such large companies see cash-strapped startups as opportunities. They can either “scoop up top talent or acquire and merge with some of these companies,” Schiada said.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

This is the logo of BD.
BD lays off 100 at biotech reagent plant in California
This is the logo of Bayer.
Bayer plans significant job cuts as it restructures
This is the logo of Pfizer.
Pfizer restructuring push hits Ireland
Multi Color DNA Structure On Black Backdrop Generative AI
Forecast 2024: Pharma industry grapples with regulatory hurdles and AI opportunities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE